Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
Portfolio Pulse from
Corcept Therapeutics announced results from its Phase 2 DAZALS study, evaluating the drug Dazucorilant in ALS patients. The study tested two doses of the drug, which is a selective cortisol modulator.
December 11, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corcept Therapeutics announced results from its Phase 2 study of Dazucorilant in ALS patients, testing two doses of the drug.
The announcement of Phase 2 study results is significant for Corcept Therapeutics as it pertains to the development of a new drug, Dazucorilant, for ALS. Positive results could lead to further trials and potential market approval, which would be beneficial for the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100